| 000 | 01853cam a2200181 4500500 | ||
|---|---|---|---|
| 005 | 20250121083952.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aVerrelle, Pierre _eauthor |
| 700 | 1 | 0 |
_a Fouillade, Charles _eauthor |
| 700 | 1 | 0 |
_a Favaudon, Vincent _eauthor |
| 245 | 0 | 0 | _aFLASH radiotherapy: State-of-the-art 2021–2022 |
| 260 | _c2022. | ||
| 500 | _a51 | ||
| 520 | _aIrreversible damage is one of the main limitations of external beam radiotherapy. FLASH radiotherapy (RT), which delivers ultra-high dose rate radiation to the target, could be a promising strategy to circumvent this issue. In FLASH-RT, a radiation dose of 5 to 15 Gy is delivered in a single microsecond pulse or as a series of pulses administered in sequence, each lasting ≤100 milliseconds. In mouse models, FLASH-RT has been shown to significantly reduce lung fibrosis while maintaining its antitumoral effects. This sparing of normal tissue from radio-induced injury has been confirmed in all organs investigated so far in both mice and large mammals, making FLASH-RT an attractive treatment approach in anticancer radiotherapy. The molecular mechanisms underlying the effects of FLASH-RT remain only partially understood. However, the evidence that this technique spares healthy tissues, especially progenitor cells, is compelling. Large companies are becoming interested in new-generation accelerators dedicated to FLASH-RT and several clinical trials have already been designed. It is hoped that the use of FLASH-RT in clinical practice will expand the indications for curative radiotherapy, particularly in children. | ||
| 786 | 0 | _nInnovations & Thérapeutiques en Oncologie | Volume 8 | 2 | 2022-03-01 | p. 98-104 | 2431-3203 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2022-2-page-98?lang=en&redirect-ssocas=7080 |
| 999 |
_c504545 _d504545 |
||